**Liquidia Corporation (LQDA) has shown significant growth potential, with its stock gaining momentum as it transitions to a commercial-stage biopharmaceutical firm focusing on rare cardiopulmonary diseases. The company’s lead product, YUTREPIA, has fueled this upward trajectory, highlighted by a sharp increase in earnings estimate revisions—current-year EPS projections have jumped 98%, while next year’s estimates are up 65%.**
**The company’s sales are expected to surge by 315% this year and an additional 67% next year, with earnings projected to increase by 471% from deeply negative levels this year, followed by a 62% rise next year. Currently, LQDA boasts a Zacks Rank #1 (Strong Buy) and is trading at a reasonable 24x forward earnings amidst its strong growth outlook.**
**Liquidia’s recent technical performance has been compelling, with the stock breaking out from a bullish continuation pattern on substantial volume, indicating potential institutional demand. As long as the stock holds above its breakout area and earnings estimates continue to rise, it remains a stock to watch.**
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
